Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12452)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 6, 2017 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 2017; 6(4): 188-200 [PMID: 28729967 DOI: 10.5527/wjn.v6.i4.188] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v6/i4/188.htm |
| Number | Citing Articles |
| 1 |
Thomas Bais, Ron T. Gansevoort, Esther Meijer. Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. Drugs 2022; 82(10): 1095 doi: 10.1007/s40265-022-01745-9
|
| 2 |
Julie Xia Zhou, Vicente E. Torres. Drug repurposing in autosomal dominant polycystic kidney disease. Kidney International 2023; 103(5): 859 doi: 10.1016/j.kint.2023.02.010
|
| 3 |
Dorota Wicher, Łukasz Obrycki, Irena Jankowska. Autosomal Recessive Polycystic Kidney Disease—The Clinical Aspects and Diagnostic Challenges. Journal of Pediatric Genetics 2021; 10(01): 001 doi: 10.1055/s-0040-1714701
|
| 4 |
Priyanka S. Radadiya, Mackenzie M. Thornton, Emily A. Daniel, Jessica Y. Idowu, Wei Wang, Brenda Magenheimer, Dharmalingam Subramaniam, Pamela V. Tran, James P. Calvet, Darren P. Wallace, Madhulika Sharma. Quinomycin A reduces cyst progression in polycystic kidney disease. The FASEB Journal 2021; 35(5) doi: 10.1096/fj.202002490R
|
| 5 |
Yong Joon Kim, Joon Kim. Therapeutic perspectives for structural and functional abnormalities of cilia. Cellular and Molecular Life Sciences 2019; 76(19): 3695 doi: 10.1007/s00018-019-03158-6
|
| 6 |
Ivana Capuano, Pasquale Buonanno, Eleonora Riccio, Maria Amicone, Antonio Pisani. Therapeutic advances in ADPKD: the future awaits. Journal of Nephrology 2022; 35(2): 397 doi: 10.1007/s40620-021-01062-6
|
| 7 |
Roman-Ulrich Müller, Bernhard Schermer. Hippo signaling—a central player in cystic kidney disease?. Pediatric Nephrology 2020; 35(7): 1143 doi: 10.1007/s00467-019-04299-3
|
| 8 |
Giovanni Piscopo. Rene policistico autosomico dominante: dalla patogenesi alla terapia. Giornale di Clinica Nefrologica e Dialisi 2022; 34(1): 109 doi: 10.33393/gcnd.2022.2489
|
| 9 |
Ameya Patil, William E. Sweeney, Cynthia G. Pan, Ellis D. Avner, Meral Gunay-Aygun. Novel Treatments for Polycystic Kidney Disease. Translational Science of Rare Diseases 2019; 4(1-2): 77 doi: 10.3233/TRD-190040
|
| 10 |
Julie Xia Zhou, Vicente E. Torres. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon. Advances in Kidney Disease and Health 2023; 30(3): 245 doi: 10.1053/j.akdh.2023.01.003
|
| 11 |
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, Francesca Musumeci, Anna Carbone, Silvia Schenone. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. International Journal of Molecular Sciences 2024; 25(3): 1398 doi: 10.3390/ijms25031398
|
| 12 |
Adarsh Ghosh, Suraj D. Serai, Shyam Sunder B. Venkatakrishna, Mohini Dutt, Erum A. Hartung. Two-dimensional (2D) morphologic measurements can quantify the severity of liver disease in children with autosomal recessive polycystic kidney disease (ARPKD). Abdominal Radiology 2021; 46(10): 4709 doi: 10.1007/s00261-021-03189-3
|
| 13 |
Erum A. Hartung, Jessica Wen, Laura Poznick, Susan L. Furth, Kassa Darge. Ultrasound Elastography to Quantify Liver Disease Severity in Autosomal Recessive Polycystic Kidney Disease. The Journal of Pediatrics 2019; 209: 107 doi: 10.1016/j.jpeds.2019.01.055
|
| 14 |
Thijs R. M. Barten, Lucas H. P. Bernts, Joost P. H. Drenth, Tom J. G. Gevers. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease. Expert Opinion on Therapeutic Targets 2020; 24(6): 589 doi: 10.1080/14728222.2020.1751818
|
| 15 |
Gopala K. Rangan, Aarya Raghubanshi, Alissa Chaitarvornkit, Ashley N. Chandra, Robert Gardos, Alexandra Munt, Mark N. Read, Sayanthooran Saravanabavan, Jennifer Q.J. Zhang, Annette T.Y. Wong. Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease. Expert Opinion on Orphan Drugs 2020; 8(8): 285 doi: 10.1080/21678707.2020.1804859
|
| 16 |
Erum A. Hartung, Juan S. Calle-Toro, Carolina Maya Lopera, Jessica Wen, Robert H. Carson, Mohini Dutt, Kathryn Howarth, Susan L. Furth, Kassa Darge, Suraj D. Serai. Magnetic resonance elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease. Abdominal Radiology 2021; 46(2): 570 doi: 10.1007/s00261-020-02694-1
|
| 17 |
Jana Reiterová, Vladimír Tesař. Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. International Journal of Molecular Sciences 2022; 23(6): 3317 doi: 10.3390/ijms23063317
|
| 18 |
Tamir Diamond, Noor Nema, Jessica Wen. Hepatic Ciliopathy Syndromes. Clinical Liver Disease 2021; 18(4): 193 doi: 10.1002/cld.1114
|
| 19 |
Julia C. Fox, Susanne T. Hahnenstein, Fatima Hassan, Andrea Grund, Dieter Haffner, Wolfgang H. Ziegler. Defects of renal tubular homeostasis and cystogenesis in the Pkhd1 knockout. iScience 2024; 27(4): 109487 doi: 10.1016/j.isci.2024.109487
|
| 20 |
Valeriia Y. Vasileva, Regina F. Sultanova, Anastasia V. Sudarikova, Daria V. Ilatovskaya. Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.693130
|
| 21 |
Lucia Carolina Leal-Esteban, Benjamin Rothé, Simon Fortier, Manuela Isenschmid, Daniel B. Constam, Gregory S. Barsh. Role of Bicaudal C1 in renal gluconeogenesis and its novel interaction with the CTLH complex. PLOS Genetics 2018; 14(7): e1007487 doi: 10.1371/journal.pgen.1007487
|
| 22 |
Mitchell I. Parker, Anna S. Nikonova, Danlin Sun, Erica A. Golemis. Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease. Cellular Signalling 2020; 67: 109497 doi: 10.1016/j.cellsig.2019.109497
|
| 23 |
Xi Yang, Thomas Papoian. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human‐induced pluripotent stem cell‐derived cardiomyocytes to assess contractile effects associated with drug‐induced structural cardiotoxicity. Journal of Applied Toxicology 2018; 38(9): 1166 doi: 10.1002/jat.3611
|
| 24 |
Chelsea C. Estrada, Alejandro Maldonado, Sandeep K. Mallipattu. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. Journal of the American Society of Nephrology 2019; 30(2): 187 doi: 10.1681/ASN.2018080853
|
| 25 |
Adrián M. Ramos, Beatriz Fernández-Fernández, María Vanessa Pérez-Gómez, Sol María Carriazo Julio, María Dolores Sanchez-Niño, Ana Sanz, Marta Ruiz-Ortega, Alberto Ortiz. Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opinion on Drug Discovery 2020; 15(1): 101 doi: 10.1080/17460441.2020.1690450
|
| 26 |
Taylor Richards, Kavindiya Modarage, Soniya A. Malik, Paraskevi Goggolidou. The cellular pathways and potential therapeutics of Polycystic Kidney Disease. Biochemical Society Transactions 2021; 49(3): 1171 doi: 10.1042/BST20200757
|
| 27 |
Francesca Testa, Riccardo Magistroni. ADPKD current management and ongoing trials. Journal of Nephrology 2020; 33(2): 223 doi: 10.1007/s40620-019-00679-y
|
| 28 |
Adrian Cordido, Marta Vizoso-Gonzalez, Miguel A. Garcia-Gonzalez. Molecular Pathophysiology of Autosomal Recessive Polycystic Kidney Disease. International Journal of Molecular Sciences 2021; 22(12): 6523 doi: 10.3390/ijms22126523
|
| 29 |
Amandeep Thakur, Chetna Faujdar, Ram Sharma, Sachin Sharma, Basant Malik, Kunal Nepali, Jing Ping Liou. Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry 2022; 65(13): 8596 doi: 10.1021/acs.jmedchem.1c01946
|
| 30 |
Irene Capelli, Sarah Lerario, Francesca Ciurli, Gian Marco Berti, Valeria Aiello, Michele Provenzano, Gaetano La Manna. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights. Expert Opinion on Investigational Drugs 2024; : 1 doi: 10.1080/13543784.2024.2342327
|
| 31 |
Cynthia J. Sieben, Peter C. Harris. Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing. Kidney360 2023; 4(8): 1155 doi: 10.34067/KID.0000000000000209
|
| 32 |
Cherie Stayner, Darby G. Brooke, Michael Bates, Michael R. Eccles. Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease. Current Medicinal Chemistry 2019; 26(17): 3081 doi: 10.2174/0929867325666180508095654
|
| 33 |
Yeoungjee Cho, Allison Tong, Jonathan C. Craig, Reem A. Mustafa, Arlene Chapman, Ronald D. Perrone, Curie Ahn, Kevin Fowler, Vicente Torres, Ron T. Gansevoort, Albert C.M. Ong, Helen Coolican, Juliana Tze-Wah Kao, Tess Harris, Talia Gutman, Jenny I. Shen, Andrea K. Viecelli, David W. Johnson, Eric Au, Ragada El-Damanawi, Charlotte Logeman, Angela Ju, Karine E. Manera, Michel Chonchol, Dwight Odland, David Baron, York Pei, Benedicte Sautenet, Anjay Rastogi, Ankit Sharma, Gopala Rangan, Adeera Levin, Alan Yu, Albert Ong, Aliza Thompson, Allison Tong, Amanda Baumgart, Amelie Bernier-Jean, Amy Kelly, Andrea Viecelli, Andrew Mallett, Angela Ju, Angela Wang, Anjay Rastog, Ankit Sharma, Annie-Claire Nadeau-Fredette, Arlene Chapman, Armando Teixeira-Pinto, Ayano Kelly, Barbara Gillespie, Benedicte Sautenet, Bernard Canaud, Braden Manns, Brenda Hemmelgarn, Camilla Hanson, Carmel Hawley, Carol Pollock, Charlotte Logeman, Chia-Ter Chao, Claudia Rutherford, Curie Ahn, Daniel Sumpton, David Harris, David Johnson, David Wheeler, Djalila Mekahli, Donal O’Donoghue, Dorien Peters, Dorothee Oberdhan, Elena Balovlenkov, Emma O'Lone, Eric Au, Francesca Tentori, Frank Czerwiec, Frederic Rahbari Oskoui, Gopi Rangan, Gregory Germino, Hayne Park, Htay Htay, Hyunjin Ryu, Jenna Norton, Jenny Shen, John Gill, Jonathan C. Craig, Juliana Kao, Kai-Uwe Eckardt, Karine Manera, Kim Linh Van, Lisa Guay-Woodford, Mahesh Krishnan, Marie Hogan, Martin Howell, Meyeon Park, Michal Mrug, Michel Chonchol, Michelle Ta, Nicole Evangelidis, Peter Harris, Peter Tugwell, Pranav Garimella, Ragada El-Damanawi, Rathika Krishnasamy, Reem Mustafa, Richard McGee, Roberto Pecoits-Filho, Ron Gansevoort, Ronald Perrone, Roser Torra, Sally Crowe, Samaya Anumudu, Samuel Chan, Sarah Bernays, Shigeo Horie, Simon Carter, Suetonia Palmer, Susan Mendley, Talia Gutman, Terry Watnick, Thomas Hiemstra, Thomas Weimbs, Vicente Torres, Vivek Jha, Wim van Biesen, Wolfgang Winkelmayer, Yeoungjee Cho, York Pei, Yun Kyu Oh, David Baron, David Clark, Debra McGinty-Poteet, Dwight Odland, Elizabeth King, Frances Vickers, Helen Coolican, Jean Odland, Kevin Fowler, Lynore Lee, Marvin Vickers, Mary Johnston-Clark, Robin Dorsey, Tess Harris, Zachary Baron. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases 2021; 77(2): 255 doi: 10.1053/j.ajkd.2020.05.024
|
| 34 |
Talieh Malekshahabi, Niloofar Khoshdel Rad, Andreas L. Serra, Reza Moghadasali. Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions. Journal of Cellular Physiology 2019; 234(8): 12451 doi: 10.1002/jcp.28094
|
| 35 |
Sebastian Strubl, Jacob A. Torres, Alison K. Spindt, Hannah Pellegrini, Max C. Liebau, Thomas Weimbs. STAT signaling in polycystic kidney disease. Cellular Signalling 2020; 72: 109639 doi: 10.1016/j.cellsig.2020.109639
|
| 36 |
Jiahe Qiu, Gregory G. Germino, Luis F. Menezes. Mechanisms of Cyst Development in Polycystic Kidney Disease. Advances in Kidney Disease and Health 2023; 30(3): 209 doi: 10.1053/j.akdh.2023.03.001
|
| 37 |
Eric G. Benz, Erum A. Hartung. Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease. Pediatric Nephrology 2021; 36(9): 2639 doi: 10.1007/s00467-020-04869-w
|
| 38 |
Claudia Dafinger, Amrei M. Mandel, Alina Braun, Heike Göbel, Kathrin Burgmaier, Laura Massella, Antonio Mastrangelo, Jörg Dötsch, Thomas Benzing, Thomas Weimbs, Bernhard Schermer, Max C. Liebau. The carboxy‐terminus of the human ARPKD protein fibrocystin can control STAT3 signalling by regulating SRC‐activation. Journal of Cellular and Molecular Medicine 2020; 24(24): 14633 doi: 10.1111/jcmm.16014
|
| 39 |
Huixia Li, Chunli Wang, Ruochen Che, Bixia Zheng, Wei Zhou, Songming Huang, Zhanjun Jia, Aihua Zhang, Fei Zhao, Guixia Ding. A Potential Therapy Using Antisense Oligonucleotides to Treat Autosomal Recessive Polycystic Kidney Disease. Journal of Clinical Medicine 2023; 12(4): 1428 doi: 10.3390/jcm12041428
|
| 40 |
Suraj D. Serai, Hansel J. Otero, Juan S. Calle-Toro, Jeffrey I. Berman, Kassa Darge, Erum A. Hartung. Diffusion tensor imaging of the kidney in healthy controls and in children and young adults with autosomal recessive polycystic kidney disease. Abdominal Radiology 2019; 44(5): 1867 doi: 10.1007/s00261-019-01933-4
|
| 41 |
Max Duong Phu, Stefan Bross, Martin D. Burkhalter, Melanie Philipp. Limitations and opportunities in the pharmacotherapy of ciliopathies. Pharmacology & Therapeutics 2021; 225: 107841 doi: 10.1016/j.pharmthera.2021.107841
|
| 42 |
Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf, Dominik Wolf. Small Molecules in Hematology. Recent Results in Cancer Research 2018; 212: 87 doi: 10.1007/978-3-319-91439-8_4
|
| 43 |
Adrián Cordido, Lara Besada-Cerecedo, Miguel A. García-González. The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease—A Primer for Clinicians. Frontiers in Pediatrics 2017; 5 doi: 10.3389/fped.2017.00279
|
| 44 |
Abeda Jamadar, Sreenath M. Suma, Sijo Mathew, Timothy A. Fields, Darren P. Wallace, James P. Calvet, Reena Rao. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death & Disease 2021; 12(10) doi: 10.1038/s41419-021-04248-9
|